Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Hologic, Inc. reported third quarter fiscal 2025 revenue of $1.024 billion, up 0.4% year-over-year and approximately $14 million above the high end of guidance.</li><li>Non-GAAP EPS increased 1.9% to $1.08, exceeding guidance by $0.01.</li><li>Non-GAAP operating margin remained above 30%, supported by expense discipline and tariff mitigation.</li></ul>

Hologic, Inc. reported third quarter fiscal 2025 revenue of $1.024 billion, up 0.4% year-over-year and approximately $14 million above the high end of guidance.Non-GAAP EPS increased 1.9% to $1.08, exceeding guidance by $0.01.Non-GAAP operating margin remained above 30%, supported by expense discipline and tariff mitigation.

Hologic’s $1.88 Billion Cash Cushion: Can Breast Health Finally Return To Growth?

<ul><li>Hologic's third quarter fiscal 2025 results provide a complex picture of the company's current financial health and future outlook.</li><li>Positives include solid performance in several business areas, while challenges continue to affect overall growth.</li><li>Revenue for the third quarter reached $1.024 billion, slightly increasing by 0.4% year-over-year, surpassing the high end of guidance by $14 million.</li></ul>

Hologic's third quarter fiscal 2025 results provide a complex picture of the company's current financial health and future outlook.Positives include solid performance in several business areas, while challenges continue to affect overall growth.Revenue for the third quarter reached $1.024 billion, slightly increasing by 0.4% year-over-year, surpassing the high end of guidance by $14 million.

Hologic Goes Global: Can International Expansion Offset China and Africa Headwinds?

<ul><li>Hologic reported third quarter performance that reflected gradual stabilization across its portfolio while also outlining several areas of ongoing uncertainty.</li><li>Revenue slightly exceeded internal expectations and demonstrated sequential improvement, supported by contributions from Diagnostics, progress in Breast Health, and continued strength in Surgical.</li><li>Non-GAAP earnings were modestly higher than the prior year, aided by disciplined expense management and a maintained operating margin above 30 percent.</li></ul>

Hologic reported third quarter performance that reflected gradual stabilization across its portfolio while also outlining several areas of ongoing uncertainty.Revenue slightly exceeded internal expectations and demonstrated sequential improvement, supported by contributions from Diagnostics, progress in Breast Health, and continued strength in Surgical.Non-GAAP earnings were modestly higher than the prior year, aided by disciplined expense management and a maintained operating margin above 30 percent.

Hologic About to Dominate Women’s Health? The Surge Behind Its Global Growth!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>The S&amp;P 500 made a new all-time closing high following the largely as-expected U.S.-China trade cease-fire agreement, but it did so unconvincingly. We would not call it a breakout as the market closed well off of the opening highs and not one cyclical Sector is decisively in new high territory. Overall, the market is sending mixed signals. Barring additional positive developments we believe upside is likely to be muted from here. In today’s report we highlight attractive Groups and stocks within Health Care, Services, and Technology: Diagnostic Imaging, Construction &amp; Engineering, Large-Cap, and Solar Energy.</p>

The S&amp;P 500 made a new all-time closing high following the largely as-expected U.S.-China trade cease-fire agreement, but it did so unconvincingly. We would not call it a breakout as the market closed well off of the opening highs and not one cyclical Sector is decisively in new high territory. Overall, the market is sending mixed signals. Barring additional positive developments we believe upside is likely to be muted from here. In today’s report we highlight attractive Groups and stocks within Health Care, Services, and Technology: Diagnostic Imaging, Construction &amp; Engineering, Large-Cap, and Solar Energy.

<p>The weight of the evidence suggests that the pullback has begun. This belief is supported by overbought conditions combined with the S&amp;P 500, MSCI ACWI, and nearly all Sectors hitting logical resistance. Assuming the pullback continues, the next question is how deep or damaging will it be? In this report we highlight various market/technical indicators we are monitoring, as well as pointing out attractive set ups within Consumer Discretionary and Health Care Sectors.</p>

The weight of the evidence suggests that the pullback has begun. This belief is supported by overbought conditions combined with the S&amp;P 500, MSCI ACWI, and nearly all Sectors hitting logical resistance. Assuming the pullback continues, the next question is how deep or damaging will it be? In this report we highlight various market/technical indicators we are monitoring, as well as pointing out attractive set ups within Consumer Discretionary and Health Care Sectors.

U.S. Equity Strategy: Has “the Pullback” Begun?

United States

Hologic, Inc. is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hologic Inc (HOLX US)

Hologic’s $1.88 Billion Cash Cushion: Can Breast Health Finally Return To Growth?

Hologic, Inc. reported third quarter fiscal 2025 revenue of $1.024 billion, up 0.4% year-over-year and approximately $14 million above the high...

Baptista Research

Hologic Goes Global: Can International Expansion Offset China and Africa Headwinds?

Hologic's third quarter fiscal 2025 results provide a complex picture of the company's current financial health and future outlook. Positives...

Baptista Research

Hologic About to Dominate Women’s Health? The Surge Behind Its Global Growth!

Hologic reported third quarter performance that reflected gradual stabilization across its portfolio while also outlining several areas of ongoing...

Baptista Research

All-Time Closing Highs Fails To Impress

The S&P 500 made a new all-time closing high following the largely as-expected U.S.-China trade cease-fire agreement, but it did so...

Vermilion Research

U.S. Equity Strategy: Has “the Pullback” Begun?

The weight of the evidence suggests that the pullback has begun. This belief is supported by overbought conditions combined with the S&P 500,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)